

Latest Vaccine Flip-flop Gives the Vaccine Game Away

The Venous Sinus System, where slow blood flow apparently predisposes to clots after the Astra-Zeneca Covid vaccination

By Dr. Meryl Nass

Global Research, April 07, 2021

Anthrax Vaccine 6 April 2021

All Global Research articles can be read in 51 languages by activating the "Translate

Website" drop down menu on the top banner of our home page (Desktop version).

Theme: Science and Medicine

The Astra-Zeneca "cheap and easy to store" "workhorse" vaccine causes blood clots in general, and in particular clots in the venous sinuses of the brain, which have killed or wounded a number of people, especially women under 55.

The European Medicines Agency, the European Union's regulator, said it is investigating at least 44 cases of the rare brain clots and at least 14 deaths among about 9.2 million vaccinations in 30 European countries...

As of March 29, Germany's regulator has reported 31 cases of the unusual blood clots in 2.7 million people vaccinated with the AstraZeneca vaccine, nine of whom have died.

The J and J vaccine was associated with blood clots in its clinical trial data presented to FDA. Both vaccines use an adenovirus vector to deliver DS DNA that codes for spike protein, and human cellular machinery produces this protein, for an uncertain period of time in uncertain quantities. So blood clotting may be due to the adenovirus vector, or to the spike protein, or to something entirely different.

The mRNA vaccines use mRNA to code for the spike, using cellular machinery to produce the spike protein. The end result of all 4 vaccines is similar, and again, we do not know for how long the body makes this protein.

If the spike itself induces clotting, which is a reasonable hypothesis scientists have put forth, but is unproven, then all 4 vaccines would be thrombogenic (induce clotting). Dr. Patrick Whelan tried to warn the FDA about this possibility, but was ignored. He wrote:

Meinhardt et al. (Nature Neuroscience 2020, in press) show that the spike protein in brain endothelial cells is associated with formation of microthrombi (clots), and like Magro et al. do not find viral RNA in brain endothelium. In other words, viral proteins appear to cause tissue damage without actively replicating virus.

Is it possible the spike protein itself causes the tissue damage associated with Covid-19? Nuovo et al (in press) have shown that in 13/13 brains from patients with fatal COVID-19, pseudovirions (spike, envelope, and membrane proteins) without viral RNA are present in the endothelia of cerebral microvessels.

This is frightening information, providing a strong hint of the spike protein's potential toxicity.

*

How did 20 countries deal with the clotting issue?

First they halted the vaccinations until they could review all the available data and get their narratives aligned. They then decided the A-Z vaccine did cause clots. But you cannot waste Covid vaccine (<u>unless you are Emergent BioSolutions</u>) so it had to be used. But in whom? In poorer countries of course. But what about the supplies already purchased by western Europe?

The public health leaders came up with a great idea. Restrict it, just for the elderly. If they die, there is almost always a preexisting condition to blame. But apparently that wasn't enough. So they have started testing this vaccine in children.

A few countries stopped the A-Z vaccine altogether.

France, Germany, Sweden and Canada are among those restricting its use in younger people, while Denmark and Norway have maintained a complete pause.

Can you imagine what the informed consent says? "We are testing a vaccine known to cause lethal blood clots in children, who almost never get severe Covid-therefore the benefits won't exceed the risks of the vaccine in this demographic. Your child is at greater risk of dying from the vaccine than the disease." How many parents would sign? Obviously, there must be lies on the consent form. Here is a legal case for you British barristers.

As I was writing this, the <u>news</u> appeared that the clinical trials of the A-Z vaccine in children were finally paused, just today. Which is 2-3 weeks after the blood clotting issue surfaced.

How well does the Astra-Zeneca vaccine work in the elderly? Only two months ago the leaders of France and Germany told us:

Officials in Germany <u>claim</u> the Astra-Zeneca vaccine is only 8% effective in those over 65. French President Macron has complained to Agence France Press that the A-Z vaccine was only "<u>quasi-ineffective for people over 65</u>."

So, in order to use up the supply, or perhaps for other purposes, Germany will now use the vaccine only in those over 60, and France will use it only in those over 55 — which are the age groups in whom they claimed it didn't work.

In case it is not yet clear, this latest flip-flop from Macron and Merkel reveals the truth. The purpose of the vaccines is obviously not to protect us. The vaccines enrich Pharma. The vaccine passports enable much greater control over the citizenry. There may be additional agendas. But this is clearly not about our health.

Note to readers: please click the share buttons above or below. Forward this article to your email lists. Crosspost on your blog site, internet forums. etc.

Featured image is from Collective Evolution

The original source of this article is <u>Anthrax Vaccine</u> Copyright © <u>Dr. Meryl Nass</u>, <u>Anthrax Vaccine</u>, 2021

Comment on Global Research Articles on our Facebook page

Become a Member of Global Research

Articles by: **Dr. Meryl Nass**

Disclaimer: The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: publications@globalresearch.ca

www.globalresearch.ca contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: publications@globalresearch.ca